Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

48 Week PFS Similar for MYL-1401O, Trastuzumab in HER2-Positive Metastatic Breast Cancer

Wayne Kuznar
Published: Tuesday, Jun 05, 2018

Hope Rugo, MD

Hope Rugo, MD
MYL-1401O (Ogivri; trastuzumab-dkst) added to a taxane as initial therapy followed by MYL-1401O monotherapy as maintenance resulted in a nearly identical rate of progression-free survival (PFS) at 48 weeks compared with trastuzumab (Herceptin) in patients with HER2-positive metastatic breast cancer, according to phase III findings from the HERITAGE trial presented at the 2018 ASCO Annual Meeting.1

This finding is consistent with a previously reported equivalent overall response rate (ORR) between MYL-1401O, a trastuzumab biosimilar, and the originator product as first-line therapy combined with a taxane.2

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication